Surrozen (SRZN) Expected to Announce Quarterly Earnings on Friday

Key Points

• Surrozen is expected to release its Q2 2025 earnings data on August 11th, with analysts projecting a loss of ($1.23) per share.
• The company's most recent earnings report indicated a loss of ($3.13) per share, missing estimates significantly, with revenue of $0.98 million.
• HC Wainwright maintained a "buy" rating for Surrozen, setting a price target of $32.00 for the stock.

Surrozen (NASDAQ:SRZN - Get Free Report) will likely be posting its Q2 2025 quarterly earnings results before the market opens on Friday, August 8th. Analysts expect Surrozen to post earnings of ($1.23) per share for the quarter.

Surrozen (NASDAQ:SRZN - Get Free Report) last announced its earnings results on Friday, August 8th. The company reported ($1.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.23) by $0.09. On average, analysts expect Surrozen to post $-8 EPS for the current fiscal year and $-11 EPS for the next fiscal year.

Surrozen Price Performance

SRZN stock traded up $0.53 on Friday, reaching $9.56. 10,258 shares of the company were exchanged, compared to its average volume of 11,484. Surrozen has a 12 month low of $5.90 and a 12 month high of $18.17. The stock's fifty day moving average price is $9.03 and its 200 day moving average price is $9.87. The firm has a market capitalization of $81.83 million, a PE ratio of -0.38 and a beta of 0.60.

Institutional Investors Weigh In On Surrozen

A hedge fund recently raised its stake in Surrozen stock. Geode Capital Management LLC boosted its holdings in shares of Surrozen, Inc. (NASDAQ:SRZN - Free Report) by 22.6% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 30,963 shares of the company's stock after buying an additional 5,702 shares during the period. Geode Capital Management LLC owned about 0.36% of Surrozen worth $277,000 as of its most recent SEC filing. 66.57% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a "buy" rating and set a $32.00 target price on shares of Surrozen in a research report on Monday, May 12th.

About Surrozen

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.